PMI’s acquisition of Fertin Pharma, a Danish manufacturer of gums and other oral products, indicates the company’s strategy to ensure “corporate survival” in the tobacco-alternatives sector, experts believe
Submit your access request to explore how it streamlines access to critical market and regulatory insights
"*" indicates required fields